Rigel Pharmaceuticals, Inc. (RIGL) fundamentals score
Rigel Pharmaceuticals is a biotechnology company dedicated to developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 6.3 out of 10, Mixed fundamentals
- Growth: 5.8/10
- Profitability: 7.2/10
- Financial health: 8.1/10
- Earnings quality: 1.8/10
- Valuation: 7.6/10
Scores are calculated from Rigel Pharmaceuticals, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10